Aurinia Pharmaceuticals
AUPH
73 hedge funds and large institutions have $193M invested in Aurinia Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 25 reducing their positions, and 11 closing their positions.
67% more call options, than puts
Call options by funds: $6.35M | Put options by funds: $3.81M
0% less capital invested
Capital invested by funds: $194M → $193M (-$754K)
0.52% less ownership
Funds ownership: 32.55% → 32.02% (-0.52%)
6% less funds holding
Funds holding: 78 → 73 (-5)
24% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 25
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$5.96M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$4.46M |
| 3 |
O
OrbiMed
New York
|
+$2.43M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.16M |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.99M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$2.1M |
| 3 |
Goldman Sachs
New York
|
-$1.56M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.31M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.08M |
AUPH Hedge Fund Activity: Q2 2019 in Review
73 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2019, worth a combined $193M — down 0.39% from $194M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AUPH and 6 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 19 added.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $5.96M. The largest seller was Fidelity Investments, cutting an estimated $7.99M.
- 73 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2019, down from 78 in Q1 2019.
- Funds reported $193M of Aurinia Pharmaceuticals stock for Q2 2019, down 0.39% quarter-over-quarter.
- 6 funds opened new Aurinia Pharmaceuticals positions in Q2 2019 and 11 closed out, a net change of -5 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2019 was Acuta Capital Partners, an estimated $5.96M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $7.99M sold.
Based on aggregated 13F filings for Q2 2019.